56 completed. 56 Phase 2, 9 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Completed 56 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 9 | Completed 9 |
Follow Phobic Disorders: new trials by email Literature Review of Phobic Disorders trials Research Report on Phobic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder ENX-102, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Engrail Therapeutics INC | 47 | 2025-09-05 | 2026-04-08 |
| Exploratory Safety and Efficacy of EMP-01 in Social Anxiety Disorder EMP-01, EMP-01 Placebo - Social Anxiety Disorder | Phase 2 | Completed | atai Therapeutics, Inc. | 70 | 2025-05-08 | 2026-07-31 |
| A Study of ONO-1110 in Patients With Social Anxiety Disorder ONO-1110, Placebo - Social Anxiety Disorder (SAD) | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 115 | 2025-01-31 | 2026-07-08 |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray - Social Anxiety Disorder | Phase 2 | Completed | VistaGen Therapeutics, Inc. | 61 | 2025-01-09 | 2026-11-04 |
| Social Safety Learning in the Brain Oxytocin System Oxytocin nasal spray or placebo - Social Phobia | Phase 2 | Completed | University of Washington | 121 | 2023-06-26 | 2026-06-11 |
| Cannabidiol to Reduce Anxiety Reactivity Cannabidiol, Placebo - Social Anxiety, Social Anxiety Disorder | Phase 2 | Completed | University of California, San Diego | 63 | 2023-04-19 | 2025-01-08 |
| Cannabidiol as a Treatment for Social Anxiety Disorder (R61) Cannabidiol, Placebo - Social Anxiety Disorder | Phase 2 | Completed | NYU Langone Health | 60 | 2023-01-26 | 2026-01-07 |
| Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder Cannabidiol oral solution, Placebo - Social Anxiety Disorder | Phase 2 | Completed | EmpowerPharm Inc. | 239 | 2022-10-27 | 2024-11-21 |
| Arthritis Ease Study Virtual Reality Nature scene plus heart rate variability biofeedback phone application - Knee Osteoarthritis, Chronic Pain | Phase 1 / Phase 2 | Completed | Arizona State University | 36 | 2022-09-15 | 2024-09-23 |
| Social Anxiety MDMA-Assisted Therapy Investigation MDMA, Psychotherapy - Social Anxiety Disorder | Phase 2 | Completed | Jason B Luoma | 90 | 2022-04-13 | 2025-08-28 |
| A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder 225 mg BNC210, 675 mg BNC210, Placebo - Social Anxiety Disorder | Phase 2 | Completed | Bionomics Limited | 151 | 2022-02-02 | 2025-03-18 |
| Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety VQW-765, Placebo - Performance Anxiety | Phase 2 | Completed | Vanda Pharmaceuticals | 230 | 2021-02-23 | 2024-03-20 |
| Intelligent Virtual Reality Therapy System and Testing Its Clinical Efficacy Intelligent Virtual Reality Therapy System (IVRTS) - Phobias, Acrophobia | Phase 1 / Phase 2 | Completed | University College of Medical Sciences, India | 500 | 2018-02-05 | 2020-11-09 |
| The Modular Protocol for Mental Health (MPMH) The Modular Protocol for Mental Health, Treatment-as-usual - Major Depressive Disorder, Generalized Anxiety Disorder | Phase 1 / Phase 2 | Completed | Medical Research Council Cognition and Brain Sciences Unit | 43 | 2017-07-18 | 2020-09-29 |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety Pegasys-VR, Social Effectiveness Therapy for Children - Anxiety Disorders | Phase 2 | Completed | University of Central Florida | 43 | 2016-06-01 | 2018-10-19 |
| Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy - Phobias, Claustrophobia | Phase 1 / Phase 2 | Completed | University of Texas at Austin | 112 | 2015-08-01 | 2022-12-28 |
| A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder JNJ-42165279, Placebo - Phobic Disorders | Phase 2 | Completed | Janssen Research & Development, LLC | 150 | 2015-06-11 | 2025-04-29 |
| Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a CERC-501, placebo - ANXIETY DISORDERS (or Anxiety and Phobic Neuroses) | Phase 2 | Completed | Duke University | 163 | 2015-06-01 | 2019-01-08 |
| Brief Behavioral Treatment for Anxiety in Young Children Parent-Led Exposure Therapy, Treatment As Usual - Obsessive-compulsive Disorder, Social Phobia | Phase 1 / Phase 2 | Completed | University of South Florida | 58 | 2014-01-01 | 2016-10-06 |
Showing 20 of 56. Sign in to see all of them.
Phobia, Social (45) · Anxiety Disorders (18) · Generalized Anxiety Disorder (12) · Anxiety, Separation (8) · Panic Disorder (4) · Agoraphobia (3) · Obsessive-Compulsive Disorder (3) · Phobia, Specific (3) · Psychological Well-Being (3) · Acrophobia (2) · Aerophobia (2) · Depressive Disorder, Major (2) · Mental Disorders (2) · Stress Disorders, Post-Traumatic (2)
Mental Disorders (54) · Anxiety Disorders (38) · Neurodevelopmental Disorders (8) · Behavior (4) · Mood Disorders (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Personal Satisfaction (3) · Signs and Symptoms (3) · Depressive Disorder (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Stress Disorders, Traumatic (2) · Trauma and Stressor Related Disorders (2)
Cognitive Behavioral Therapy (5) · Paroxetine (5) · Cannabidiol (3) · Cycloserine (3) · Escitalopram (2) · Hypericum extract LI 160 (2) · Psychotherapy (2) · Therapeutics (2) · Virtual Reality Exposure Therapy (2) · vestipitant (2) · Aticaprant (1) · Commerce (1) · Counseling (1) · Dexetimide (1) · Educational Status (1)
GlaxoSmithKline (4) · Duke University (3) · University of California, San Diego (3) · NYU Langone Health (2) · National Center for Complementary and Integrative Health (NCCIH) (2) · START Clinic for Mood and Anxiety Disorders (2) · Tel Aviv University (2) · University of California, Los Angeles (2) · University of South Florida (2) · University of Texas at Austin (2) · VU University of Amsterdam (2) · Arizona State University (1) · Avera Pharmaceuticals (1) · Bionomics Limited (1) · Charite University, Berlin, Germany (1)
United States (38) · Canada (5) · Norway (5) · Germany (3) · Sweden (3) · Israel (2) · Netherlands (2) · South Africa (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Chile (1) · Costa Rica (1) · Denmark (1) · Finland (1)
Angela Fang, PhD (1) · Asle Hoffart, Dr Psychol (1) · Carrie Masia, Ph.D. (1) · Cary Savage, PhD (1) · Charles Taylor, PhD (1) · Deborah C Beidel, Ph.D. (1) · Denise A Chavira, PhD (1) · Einar Heiervang, MD (1) · Eric A Storch, Ph.D. (1) · Esther Blessing, MD (1) · Finn-Magnus Borge, Cand Psychol (1) · Frances R Levin, MD (1)
PMID 12296495, PMID 16540816, PMID 20018493, PMID 20235773, PMID 21492829, PMID 21639653, PMID 22233247, PMID 22659077, PMID 23108976, PMID 23257654, PMID 23357440, PMID 23398031, PMID 24666527, PMID 24700254, PMID 24727078, PMID 25461793, PMID 25637909, PMID 26203478, PMID 26583954, PMID 26647901, PMID 26833396, PMID 27002215, PMID 27435286, PMID 28165762, PMID 28475502, PMID 28559206, PMID 29195188, PMID 29754811, PMID 29792485, PMID 30007519, PMID 30082367, PMID 30138014, PMID 30696471, PMID 33070154, PMID 34284836, PMID 37520237, PMID 39954310
2014 (1), R01MH059308 (1), R01MH081881 (1), R34MH086668 (1), R34MH090149 (1), R34MH095210 (1)